Cure My Disease

Don't miss your cure!

 Log in / Sign up

Spleen surgery may reshape cholesterol in cirrhosis

NCT ID NCT07811700

Symptom relief Sponsor: Northern Jiangsu People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

People with liver cirrhosis often have abnormal cholesterol and triglyceride levels. Researchers at Northern Jiangsu People's Hospital are following 150 cirrhosis patients who undergo laparoscopic splenectomy and azygoportal disconnection, a common operation for bleeding caused by portal hypertension. The team will measure blood fats before surgery and for one year afterward to see whether the operation changes these levels and to identify who improves or worsens.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
laparoscopic splenectomy and azygoportal disconnection surgery
What this could lead to
If surgery improves cholesterol and triglyceride levels, doctors could use it as part of metabolic care for people with cirrhosis. It may also help them predict whose lipids will worsen after the operation.
What could go wrong
This is a single-center observational study of 150 people, so it can show associations but not prove that surgery causes lipid changes. Cirrhosis itself, diet, and medications could all affect the results, and findings may not apply to sicker patients or other hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

150 people

The number who actually took part.

Started

May 2022

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Retrospective, single-center, observational cohort study. Medical records of patients with cirrhosis, splenomegaly and hypersplenism, and portal hypertension bleeding who had undergone Laparoscopic Splenectomy and Azygoportal Disconnection (LSD) were reviewed. Preoperative baseline data and postoperative data at 3, 6, 9, and 12 months were extracted to evaluate dynamic changes in lipid profiles within 1 year postoperatively.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18-80 years, male or female 2. Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging) 3. Splenomegaly and hypersplenism 4. History of portal hypertension bleeding (esophageal and gastric variceal bleeding ) 5. Child-Pugh Class A or B liver function 6. Ability to complete 12-month follow-up Exclusion Criteria: 1. Child-Pugh Class C liver cirrhosis 2. Previous abdominal surgery precluding safe laparoscopic splenectomy and azygoportal disconnection 3. Severe cardiac, pulmonary, cerebrovascular dysfunction; malignant tumors; primary hematological disorders 4. Metabolic/endocrine diseases: Familial hyperlipidemia; uncontrolled severe diabetes mellitus, thyroid dysfunction, nephrotic syndrome; use of lipid-lowering drugs, hormones, or other drugs affecting blood lipids within 1 month before surgery. 5. Infections/inflammatory diseases: Active hepatitis, severe infections, or autoimmune diseases. 6. Cirrhotic complications (hepatic encephalopathy, refractory ascites) within 1 month before surgery 7. Pregnancy or lactation 8. Poor compliance, inability to complete follow-up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cirrhosis, liver are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis hypersplenism portal hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cirrhosis, liver Lipid profiles Portal hypertension Splenectomy; status

Contacts and locations

Locations

  • Clinical Medical College of Yangzhou University

    Yangzhou, Jiangsu, 225001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.